{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:45:16Z","timestamp":1760028316537},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1007\/s10557-008-6079-x","type":"journal-article","created":{"date-parts":[[2008,1,24]],"date-time":"2008-01-24T16:19:44Z","timestamp":1201191584000},"page":"1-2","source":"Crossref","is-referenced-by-count":8,"title":["Recombinant Human Epo Treatment: Beneficial in Chronic Kidney Disease, Chronic Heart Failure, or Both?"],"prefix":"10.1007","volume":"22","author":[{"given":"A. M. S.","family":"Belonje","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,25]]},"reference":[{"key":"6079_CR1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1523-1755.2004.00450.x","volume":"65","author":"M Jones","year":"2004","unstructured":"Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 2004;65:757\u201367.","journal-title":"Kidney Int"},{"key":"6079_CR2","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085\u201398.","journal-title":"N Engl J Med"},{"key":"6079_CR3","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","volume":"355","author":"TB Drueke","year":"2006","unstructured":"Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071\u201384.","journal-title":"N Engl J Med"},{"key":"6079_CR4","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1056\/NEJMc066568","volume":"356","author":"MA Pfeffer","year":"2007","unstructured":"Pfeffer MA. An ongoing study of anemia correction in chronic kidney disease. N Engl J Med 2007;356:959\u201361.","journal-title":"N Engl J Med"},{"key":"6079_CR5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jacc.2006.11.024","volume":"49","author":"P Ponikowski","year":"2007","unstructured":"Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007;49:753\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"6079_CR6","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/eurheartj\/ehm328","volume":"28","author":"DJ Veldhuisen van","year":"2007","unstructured":"van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007;28:2208\u201316.","journal-title":"Eur Heart J"},{"key":"6079_CR7","doi-asserted-by":"crossref","unstructured":"Pappas KD, Gouva CD, Katopodis KP, et al. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. Cardiovasc Drugs Ther. 2007; DOI 10.1007\/s10557-007-6075-6 .","DOI":"10.1007\/s10557-007-6075-6"},{"key":"6079_CR8","doi-asserted-by":"crossref","unstructured":"Lipsic E, Westenbrink B, van der Meer P, et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail. 2007;in press (December 10).","DOI":"10.1016\/j.ejheart.2007.10.008"},{"key":"6079_CR9","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1073\/pnas.0409329102","volume":"102","author":"F Fiordaliso","year":"2005","unstructured":"Fiordaliso F, Chimenti S, Staszewsky L, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia\u2013reperfusion injury. Proc Natl Acad Sci U S A 2005;102:2046\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6079_CR10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jacc.2005.03.044","volume":"46","author":"P Meer van der","year":"2005","unstructured":"van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125\u201333.","journal-title":"J Am Coll Cardiol"},{"key":"6079_CR11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/01.fjc.0000140209.04675.c3","volume":"44","author":"E Lipsic","year":"2004","unstructured":"Lipsic E, van der Meer P, Henning RH, et al. Timing of erythropoietin treatment for cardioprotection in ischemia\/reperfusion. J Cardiovasc Pharmacol 2004;44:473\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"key":"6079_CR12","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ejheart.2004.03.012","volume":"6","author":"P Meer van der","year":"2004","unstructured":"van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia\u2013reperfusion injury. Eur J Heart Fail 2004;6:853\u20139.","journal-title":"Eur J Heart Fail"},{"key":"6079_CR13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10557-006-7680-5","volume":"20","author":"E Lipsic","year":"2006","unstructured":"Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, van Zonneveld AJ, Schoemaker RG, van Gilst WH, Zijlstra F, van Veldhuisen DJ. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006;20:135\u201341.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6079_CR14","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/eurheartj\/ehm177","volume":"28","author":"BD Westenbrink","year":"2007","unstructured":"Westenbrink BD, Lipsic E, van der Meer P, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007;28:2018\u201327.","journal-title":"Eur Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-008-6079-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T09:06:43Z","timestamp":1557220003000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-008-6079-x"}},"subtitle":["Editorial to: \u201cCorrection of Anemia with Erythropoietin in Chronic Kidney Disease (Stage 3 or 4): Effects on Cardiac Performance by Pappas et al.\u201d"],"short-title":[],"issued":{"date-parts":[[2008,1,25]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["6079"],"URL":"https:\/\/doi.org\/10.1007\/s10557-008-6079-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,25]]}}}